Botulinum Neurotoxins and Nervous System Future Challenges for Novel Indications

• Awduron Eraill: Luvisetto, Siro (Golygydd)
• Fformat: Electronig Pennod Llyfr
• Iaith: Saesneg
• Cyhoeddwyd: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Pynciau: Medicine; botulinum toxin; limb tremors; muscle selection; biological effect; various cell types; neurotransmitter; dermatology; novel indication; botulinum neurotoxin; masticatory system; maxillofacial bone; dental occlusion; orthognathic surgery; sialorrhoea; drooling; salivary glands; swallowing; eccrine glands; onabotulinumtoxin A; incobotulinumtoxin A; botulinum neurotoxins; botulinum neurotoxin serotype A; heavy chain; botulinum neurotoxin serotype a heavy chain (BoNT/A HC); spinal cord injury (SCI); nerve regeneration; growth associated protein 43 (GAP-43); superior cervical ganglion 10 (SCG10); neuronal processes; neural regeneration; Schwann cells; glia; spinal cord; immunohistochemistry; allodynia; weight bearing; sciatic static index; walking track analysis; itch; SNARE; VAMP; mast cells; compound 48/80; chloroquine; spasticity; botulinum toxin type A; appropriate treatment; Therapeutic Index; pruritus; antipruritic; clinical; experimental; BoNT/A; astroglia; interleukins; microglia; TLR2; TLR4; Snap-23; pain; cerebral palsy; botulinum toxin A; complex regional pain syndrome; lumbar sympathetic ganglion block; chronic pelvic pain; overactive detrusor; vaginism; temporomandibular joint dislocation; lateral pterygoid muscle; botulinum toxin therapy; synaptic transmission; SNAP-25; epilepsy; Parkinson's disease; neurotransmission blockade; electrical activity; prion disease; new indications; formulation; delivery; refractory chronic migraine; tension headache; medication overuse headache; prophylactic treatment; XEOMIN®; BTX; central neuropathic pain; spinal cord injury; post-stroke shoulder pain; mouse test; Clostridium tetani; botulinum antitoxin; food safety; abobotulinumtoxinA; upper limb spasticity; post-stroke; early use; ONTIME; clinical trial; human; urodynamics; botulinum neurotoxin-A; basal ganglia; interspecies differences in motor behavior; mouse; rat; interneurons; hand tremor; treatment; electromyography; kinematics; essential tremor; dystonic tremor; tremor; movement disorders; Botulinum toxin; upper limb biomechanics; joint biomechanics; diagnostic guidance; clinical decision support; spastic paresis; electrical stimulation; stroke management; rehabilitation; hand; n/a
• Mynediad Ar-lein: DOAB: download the publication; DOAB: description of the publication

This book collects 25 scientific articles from laboratories around the world, all of which use botulinum neurotoxins as the main protagonists of their studies. The use of botulinum neurotoxin in medicine, following its ability to inhibit the effects of various disorders of different etiology on the...